FDA Approves Lifyorli Combo for Platinum-Resistant Ovarian Cancer, Showing Survival Gain FDA clears Corcept’s Lifyorli with nab-paclitaxel for platinum-resistant ovarian-type cancers, the first cortisol-receptor blocker to extend survival.

FDA Approves Lifyorli Combo for Platinum-Resistant Ovarian Cancer, Showing Survival Gain

#ovariancancer #fda #chemotherapy #drugapproval #oncology

BioXcel Therapeutics: FDA Accepts IGALMI Application FDA accepted BioXcel's IGALMI filing on Apr 1, 2026; review enters a 6–10 month window per FDA timelines and creates defined near-term catalysts.

BioXcel Therapeutics: FDA Accepts IGALMI Application: FDA accepted BioXcel's IGALMI filing on Apr 1, 2026; review enters a 6–10 month window per FDA timelines and creates defined near-term catalysts. 👈 Read full analysis #BioXcelTherapeutics #IGALMI #FDANews #Pharmaceuticals #DrugApproval

🚨 #BREAKING: The @fda.gov has approved Denalitx's Tividenofusp alfa-eknm (AVLAYAH)❗

The drug is indicated for treatment of neurologic manifestations of Hunter syndrome (mucopolysaccharidosis type II [ #MPSII ]) in pediatric patients.

#FDA #FDANews #DrugApproval #Neurology #Wow

💊FDA Approval Update | 🚨#FDA has approved the FIRST #generic version of #Flovent HFA (fluticasone propionate inhalation #aerosol) for #asthma maintenance therapy
What impact will this have on asthma care and drug accessibility?
#FDADecision #DrugApproval #RespiratoryMedicine

Policy shift favors one pivotal trial, aiming to cut costs, speed access and reshape how therapies for aging reach patients.

vist.ly/4sqrh

#longevity #FDA #DrugApproval #RegulatoryReform #BiotechPolicy #ClinicalDevelopment #AgingTherapeutics #HealthEconomics

5 rare disease breakthrough drugs approved in China.
Faster approvals are turning “untreatable” into treatable.

When treatment becomes possible,
rare no longer means hopeless.

📩 info@dengyuemed.com
🔗 dengyuemed.com

#RareDisease #OrphanDrugs #ChinaPharma #Biotech #DrugApproval

What Does a Regulatory Affairs Specialist Do?

What Does a Regulatory Affairs Specialist Do?

https://zpr.io/GnVKgpkjUS4U

#RegulatoryAffairs #PharmaceuticalJobs #ComplianceExpert #DrugApproval #HealthcareRegulations #careers #jobs #pharma #pharmiweb

Search Jobs in Pharma: https://phrmwb.com/careers

Why drug approval in Canada should not rely on foreign regulators | The-14 Canada should not outsource drug approvals to the FDA or EMA without proof it improves safety, value, or access for patients, not just faster pharma profits.

Why drug approval in Canada should not rely on foreign regulators
#Canada #Health #DrugApproval #PharmaIndustry #PublicHealth #FDA #EMA #HealthcarePolicy #PatientSafety #MedicalEthics #Regulation #BigPharma #HealthPolicy #Politics #EvidenceBasedMedicine
the-14.com/why-drug-app...

First Approval in Commissioner's National Priority Voucher Pilot Program Strengthens Domestic Antibiotic Manufacturing Capacity The U.S. Food and Drug Administration today approved Augmentin XR (amoxicillin-clavulanate potassium) under the Commissioner's National Priority Voucher (CNPV) pilot program, marking the first approva...

FDA approves Augmentin XR under the Commissioner’s National Priority Voucher (CNPV) pilot program—the first approval through this pathway—with review completed in just 2 months, significantly accelerating timelines for priority antibiotic therapies.

#FDA #DrugApproval #Antibiotics #PublicHealth

🔗 Read more: bit.ly/ONCOnews21N-3

#ONCOnews #OncoAlert #OncEd #Oncology #CancerUpdates #FDAApproval #Hematology #DrugApproval

La NMPA de China otorga la aprobación condicional para la inyección de remestemcel-L-rknd

📩 info@dengyuemed.com
🔗https://dengyuepharma.com

#Ryoncil #remestemcelLrknd #aGVHD #GraftVersusHostDisease #StemCellTherapy #NMPA #DrugApproval #CellTherapy #Biotech #Hematology

China’s NMPA Grants Conditional Approval for Taletrectinib Adipate Capsules

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#ChinaNMPA #DrugApproval #TaletrectinibAdipate #Dabole #ROS1Positive #NSCLC #LungCancer #TargetedTherapy #Oncology #BaoyuanBiopharma

China NMPA Approves Donanemab Injection for Marketing

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#Donanemab #EliLilly #AlzheimersDisease #NMPA #DrugApproval #MonoclonalAntibody #Neuroscience #ChinaPharma

China NMPA Approves Secituzumab Tirumotecan for Injection

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#ChinaNMPA #DrugApproval #SecituzumabTirumotecan #ADC #TROP2 #TripleNegativeBreastCancer #KelunBiotech #Jiatailai

China NMPA Grants Conditional Approval for Garsorasib Tablets

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#ChinaNMPA #DrugApproval #Garsorasib #NSCLC #KRASG12C #InnovativeDrug #ChiataiTianqing #LungCancer

Gene editing stocks surged after Bloomberg reported the FDA plans to streamline approvals for gene editing therapies.

#CRSP #CRSPStock #CRISPR #CRSPNews #CRSPStockNews #CRISPRTherapeuticsStock #CRISPRStock #GeneEditing #Biotech #GeneTherapy #FDA #DrugApproval #Editas #Intellia
$CRSP

China NMPA Approves Spuqibai Monoclonal Antibody Injection for Market

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#KeymedBio #StapokibartInjection #InnovativeDrugs #AtopicDermatitis #IL4RAntibody #BiopharmaChina #BiotechInnovation #ChinesePharmaceuticals #DrugApproval #Biologics

China NMPA Approves Funakizumab Injection for Moderate-to-Severe Plaque Psoriasis

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#NMPA #DrugApproval #MonoclonalAntibody #IL17A #Psoriasis #BiopharmaChina #InnovativeDrug

China NMPA Approves Xeligekimab Injection for the Treatment of Plaque Psoriasis

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#DrugApproval #Psoriasis #IL17A #Biologics #ChinaPharma #DengYueMedicine

Health Canada Approves First Alzheimer’s Drug, Lecanemab, After Lengthy Review Process Health Canada approves lecanemab, offering hope for Alzheimer's treatment in Canada despite challenges.

Health Canada Approves First Alzheimer’s Drug, Lecanemab, After Lengthy Review Process

Read more: 👇
www.thecanadareport.ca/featured/health-canada-l...

#healthcanada #alzheimerdrug #lecanemab #medicalnews #canadahealth #drugapproval #alzheimersresearch

#ONCOnews #OncoAlert #OncEd #Oncology #CancerTreatment #DrugApproval

Trump either

does not understand the robust #DrugApproval process of the US government

or

is shilling disinformation for #RFKJr

US FDA declines to approve Outlook Therapeutics’ drug for eye condition (Reuters) -Outlook Therapeutics said on Thursday the U.S. health regulator has declined to approve its experimental drug to treat a type of eye condition, which causes blurred vision, sending its shares slumping nearly 70% before the bell. The U.S. Food and Drug Administration, in its so-called "complete response letter", cited a lack of substantial evidence of effectiveness in the company’s application for the drug, ONS-5010, for treating patients with wet age-related macular degeneration. This is a chronic eye disorder that causes blurred vision or a blind spot in the patient’s visual field, and is the leading cause of blindness among the elderly. The FDA’s decision marks another setback in Outlook’s prolonged efforts to enter the market, following a series of previous challenges. The company had withdrawn its application for the eye disease drug in 2022, after the FDA requested additional information. A year later, the regulator declined to approve the drug, citing manufacturing issues. "While we are very disappointed with this outcome, we intend to meet with the FDA to receive additional clarity on their requirements" to potentially approve ONS-5010, said CEO Bob Jahr. The FDA has recommended Outlook to provide additional data on the efficacy to support its application. The company’s resubmitted application was based on the results from a trial that studied the drug compared to Roche’s treatment Lucentis for improving vision in patients. In the key trial conducted by Outlook to address some of the FDA’s previous concerns, ONS-5010 failed to match Roche’s drug at eight weeks. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. Other than Lucentis, the already approved and available treatments for wet age-related macular degeneration include Regeneron’s Eylea and Roche’s Vabysmo. Outlook’s drug, under the brand name Lytenava, is approved in the European Union and the UK for the condition. ProPicks AI evaluates REGN alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if REGN is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?

Click Subscribe #FDA #OutlookTherapeutics #Pharmaceuticals #EyeHealth #DrugApproval

US FDA declines to approve PTC Therapeutics’ oral drug for rare genetic disorder By Puyaan Singh and Kamal Choudhury (Reuters) -The U.S. Food and Drug Administration has denied approval for PTC Therapeutics (NASDAQ:PTCT)’ oral medication for a rare genetic disorder with limited treatment options, the company said on Tuesday. In its so-called Complete Response Letter, the FDA said the data did not provide substantial efficacy evidence for the drug, vatiquinone, in treating Friedreich’s ataxia and that a separate study was needed before resubmitting the application. At least three analysts said the regulator’s rejection was not surprising and that expectations had been low heading into the decision. PTC (NASDAQ:PTC)’s shares reversed premarket losses to rise more than 8% in morning trading. The FDA approved Sephience - PTC’s oral therapy for a rare metabolic disorder called phenylketonuria - last month, potentially countering revenue declines due to regulatory scrutiny and competition from cheaper rivals for its top-selling muscular disorder therapies, Translarna and Emflaza. "We see today’s CRL as a clearing event since investors can now turn their focus to the Sephience launch," J.P.Morgan analysts said in a client note. The company said it planned to meet with FDA officials to discuss potential next steps. "We are of course disappointed by the FDA’s decision to not approve vatiquinone," CEO Matthew Klein said, adding that the data till date demonstrated that the drug could be safe and effective for children and adults living with the disorder. Friedreich’s ataxia is a rare genetic disorder that causes progressive damage to the nervous system, often leading to difficulty in walking, speech problems and heart complications. The disease tends to develop in children and teenagers and gradually worsens over time. Currently, Biogen (NASDAQ:BIIB)’s Skyclarys remains the only FDA-approved treatment for Friedreich’s ataxia. Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks AI – 6 model portfolios fueled by AI stock picks with a stellar performance this year... In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies. So if BIIB is on your watchlist, it could be very wise to know whether or not it made the ProPicks AI lists.

Click Subscribe #FDA #PTCTherapeutics #DrugApproval #GeneticDisorder #RareDiseases

FDA expands Bayer’s Kerendia label to include certain heart failure patients The drug is part of an expanding cardio-renal-metabolic care portfolio, is approved for CKD associated with type 2 diabetes.

The US FDA has approved Bayer’s Kerendia (finerenone) for adults with heart failure and left ventricular ejection fraction (LVEF) of 40% or higher.

#news #KERENDIA #HeartFailure #HFpEF #HFmrEF #Cardiology #HeartHealth #FDAApproval #PharmaNews #DrugApproval

FDA expands Bayer’s Kerendia label to include certain heart failure patients The drug is part of an expanding cardio-renal-metabolic care portfolio, is approved for CKD associated with type 2 diabetes.

The US FDA has approved Bayer’s Kerendia (finerenone) for adults with heart failure and left ventricular ejection fraction (LVEF) of 40% or higher.

#news #KERENDIA #HeartFailure #HFpEF #HFmrEF #Cardiology #HeartHealth #FDAApproval #PharmaNews #DrugApproval

FDA Nears Crucial Decision on NeuroClear: What the Science Reveals About the New Alzheimer’s Drug "The FDA is set to rule on NeuroClear, a new Alzheimer's drug, by July 18. An in-depth look at the clinical trial data, the drug's mechanism, and the stakes."

FDA to Decide on New Alzheimer's Drug NeuroClear

#FDA #Alzheimers #NeuroClear #DrugApproval #Neuroscience #HealthTech #FactRage #FactRageNews

tglm.us/Rtnta

FDA Plans to Implement AI in Healthcare Decision-Making, Raising Expert Concerns | AI News Brew <p>The U.S. Food and Drug Administration (FDA) is planning to incorporate artificial intelligence (AI) into its decision-making processes for various health-related fields, according to a recent artic...

FDA Plans to Implement AI in Healthcare Decision-Making, Raising Expert Concerns
ainewsbrew.com/article/4526

#FDAAI #HealthcareAI #AIRegulation #DrugApproval #PatientSafety #MedicalInnovation #AIEthics #HealthTech

Want to understand regulatory approval for medicines? Start with this.

Watch here: www.youtube.com/watch?v=taJX...

#DrugApproval #PharmaRegulations #MedicalInnovation #SkyHealthAcademy

Want to know how new medicines get approved? Start here.

Watch here: www.youtube.com/watch?v=taJX...

#DrugApproval #ClinicalDevelopment #MedicalInnovation #SkyHealthAcademy